 Fennec Pharmaceuticals Inc NASDAQ: FENC has resubmitted its marketing application to the FDA seeking approval for Pedmark formulated sodium thiosulfate for the prevention of ototoxicity toxic to the ear induced by cisplatin chemotherapy in patients one month, to less than 18 years, with localized, non-metastatic, solid tumors. The resubmission follows receipt of final minutes from a Type A meeting with the FDA. 